Current Immunotherapeutic Approaches in Pancreatic Cancer

被引:69
作者
Koido, Shigeo [1 ,2 ,3 ]
Homma, Sadamu [3 ]
Takahara, Akitaka [1 ]
Namiki, Yoshihisa [2 ]
Tsukinaga, Shintaro [1 ]
Mitobe, Jimi [1 ]
Odahara, Shunichi [1 ]
Yukawa, Toyokazu [1 ]
Matsudaira, Hiroshi [1 ]
Nagatsuma, Keisuke [1 ]
Uchiyama, Kan [1 ]
Satoh, Kenichi [1 ]
Ito, Masaki [3 ]
Komita, Hideo [1 ]
Arakawa, Hiroshi [1 ]
Ohkusa, Toshifumi [1 ,2 ]
Gong, Jianlin [4 ]
Tajiri, Hisao [1 ]
机构
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058461, Japan
[2] Jikei Univ, Sch Med, Inst Clin Med & Res, Tokyo 1058461, Japan
[3] Jikei Univ, Sch Med, Dept Oncol, Inst DNA Med, Tokyo 1058461, Japan
[4] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA
来源
CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2011年
关键词
GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; CYTOTOXIC T-LYMPHOCYTES; PHASE-III TRIAL; PERSONALIZED PEPTIDE VACCINATION; UNIVERSAL TUMOR-ANTIGEN; CELL-BASED VACCINATION; HUMAN DENDRITIC CELLS; PLUS GEMCITABINE; CARCINOMA CELLS;
D O I
10.1155/2011/267539
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.
引用
收藏
页数:15
相关论文
共 132 条
  • [1] Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
    Abou-Alfa, Ghassan K.
    Letourneau, Richard
    Harker, Graydon
    Modiano, Manuel
    Hurwitz, Herbert
    Tchekmedyian, Nerses Simon
    Feit, Kevie
    Ackerman, Judie
    De Jager, Robert L.
    Eckhardt, S. Gail
    O'Reilly, Eileen M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4441 - 4447
  • [2] Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
    Abou-Alfa, Ghassan K.
    Chapman, Paul B.
    Feilchenfeldt, Jonas
    Brennan, Murray F.
    Capanu, Marinela
    Gansukh, Bolorsukh
    Jacobs, Gria
    Levin, Adrah
    Neville, Deirdre
    Kelsen, David P.
    O'Reilly, Eileen M.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (03): : 321 - 325
  • [3] Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial
    不详
    [J]. LANCET ONCOLOGY, 2008, 9 (01) : 39 - 44
  • [4] [Anonymous], CANC IMMUNOLOGY IMMU
  • [5] [Anonymous], SEMINARS ONCOLOGY S7
  • [6] [Anonymous], PANCREAS IN PRESS
  • [7] Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
    Avigan, D
    Vasir, B
    Gong, JL
    Borges, V
    Wu, ZK
    Uhl, L
    Atkins, M
    Mier, J
    McDermott, D
    Smith, T
    Giallambardo, N
    Stone, C
    Schadt, K
    Dolgoff, J
    Tetreault, JC
    Villarroel, M
    Kufe, D
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (14) : 4699 - 4708
  • [8] Dendritic cells and the control of immunity
    Banchereau, J
    Steinman, RM
    [J]. NATURE, 1998, 392 (6673) : 245 - 252
  • [9] Dendritic cells as therapeutic vaccines against cancer
    Banchereau, J
    Palucka, AK
    [J]. NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) : 296 - 306
  • [10] Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
    Bauer, C.
    Bauernfeind, F.
    Sterzik, A.
    Orban, M.
    Schnurr, M.
    Lehr, H. A.
    Endres, S.
    Eigler, A.
    Dauer, M.
    [J]. GUT, 2007, 56 (09) : 1275 - 1282